Skip to main content
BioInfra Co.,Ltd. logo

BioInfra Co.,Ltd. — Investor Relations & Filings

Ticker · 199730 ISIN · KR7199730003 KO Professional, scientific and technical activities
Open in API
Filings indexed 88 across all filing types
Latest filing 2024-03-15 Annual Report
Country KR South Korea
Listing KO 199730

About BioInfra Co.,Ltd.

http://bioinfra.co.kr/?lang=en

BioInfra Co., Ltd. is a biotechnology and healthcare company specializing in innovative solutions for disease prevention and early detection, with a primary focus on oncology. The company's core technology is a proprietary multi-biomarker blood test for the early screening of eight major cancers, including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer. This in vitro diagnostic tool analyzes a small blood sample to assess cancer risk, aiming to improve patient outcomes through early intervention. Beyond diagnostics, BioInfra also engages in pharmaceutical research and development, offering clinical research services and developing cancer gene treatments.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for BioInfra Co., Ltd. for the fiscal year 2023. It contains detailed financial statements, management discussion and analysis, governance information, and operational data. It is a comprehensive annual filing submitted to the Financial Supervisory Service and the Korea Exchange. Although it is a 'correction' (정정) filing, the content is the full Annual Report itself, not just an announcement of one. FY 2023
2024-03-15 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Solicitation of Proxy Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM) of Bioinfra, including agenda items like approval of financial statements, election of directors/auditors, and remuneration limits. This document is a standard proxy solicitation material sent to shareholders to request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-11 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement regarding a decision on cash dividends ('현금ㆍ현물배당 결정'). It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This aligns perfectly with the definition for a Notice of Dividend Amount (DIV).
2024-03-08 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a 'General Meeting of Shareholders' (주주총회소집결의) issued by Bioinfra. It outlines the date, location, and agenda items (such as financial statement approval, director/auditor appointments, and dividend proposals) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation material provided to shareholders to inform them of the meeting agenda and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2024-03-08 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Bioinfra Co., Ltd. It details the date, location, agenda items (such as financial statement approval, director appointments, and dividend proposals), and procedures for electronic voting. This document is a standard proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes. According to the provided definitions, this fits the 'Proxy Solicitation & Information Statement' (PSI) category.
2024-03-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (stock option exercise) by an executive (Hwang Gyu-sang) of Bioinfra. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-03-08 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.